Quick Dispatch:
Your case reports aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your case reports aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery ships.
Need Help?
Questions about case reports aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for case reports aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery in your area.
Glucagon-Like Peptide 1 Receptor Agonists and Aspiration Risk
29.85
🔸 Should GLP-1 RAs be continued preprocedurally? 🔸 Who should stop a GLP-1 RA preoperatively? 🔸 Which patients should have their procedures postponed? Read: https://doi.org/10.1097/01.ASM.0001125664.22893.9f
23.13
Glucagon-Like Peptide 1 Receptor Agonists and Aspiration Risk
23.11
Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist
29.84
Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists - Marroquin‐Harris - 2023 - Anaesthesia
20.48
Concerns have been raised about whether the delayed gastric emptying caused by GLP-1–based medications might jeopardize patient safety during procedures that require sedation. A randomized trial takes a closer look
26.84
Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
23.62
